Cash from Operations (TTM) Chart

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -119.86M
March 31, 2026 -140.50M
December 31, 2025 -165.24M
September 30, 2025 -179.62M
June 30, 2025 -201.36M
March 31, 2025 -208.21M
December 31, 2024 -210.28M
September 30, 2024 -181.76M
June 30, 2024 -164.63M
March 31, 2024 -146.28M
December 31, 2023 -132.18M
September 30, 2023 -152.21M
June 30, 2023 -164.76M
March 31, 2023 -163.89M
December 31, 2022 -177.35M
September 30, 2022 -169.66M
June 30, 2022 -162.44M
March 31, 2022 -163.55M
December 31, 2021 -163.80M
September 30, 2021 -169.32M
June 30, 2021 -183.34M
March 31, 2021 -175.24M
Date Value
December 31, 2020 -179.84M
September 30, 2020 -98.72M
June 30, 2020 -70.80M
March 31, 2020 -65.75M
December 31, 2019 -40.67M
September 30, 2019 -80.37M
June 30, 2019 -61.32M
March 31, 2019 -52.25M
December 31, 2018 -45.71M
September 30, 2018 -72.10M
June 30, 2018 -92.24M
March 31, 2018 -101.67M
December 31, 2017 -9.417M
September 30, 2017 2.295M
June 30, 2017 13.23M
March 31, 2017 29.49M
December 31, 2016 -49.93M
September 30, 2016 -44.54M
June 30, 2016 -39.44M
March 31, 2016 -9.089M
December 31, 2015 -5.403M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Recursion Pharmaceuticals, Inc. -350.48M
Geron Corp. -114.38M
Halozyme Therapeutics, Inc. 818.60M
Novavax, Inc. -36.90M
AVITA Medical, Inc. -24.71M